,74 Some antibody–drug conjugates (ADCs) such as trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan (T-Dxd, DS-8201) have also displayed encouraging activities against HER2-overexpressing and HER2-mutated NSCLC, with ORRs of 20–55%.75 Here, ERBB2 is linked to non-small cell lung carcinoma.